Search Videos and More
News
Study Identifies Factors in Tumors’ Response to Natural Killer Cells
The immune cells known as natural killer (NK) cells are part of the body’s first line of defense against cancer. Many efforts are underway to harness NK cells as a form of cancer immunotherapy, but a critical question in the field remains: Why do some tumors tend to be sensitive to NK cells’ attacks while others are more resistant?
Video
Adjuvant Palbociclib in HR+/HER2 Early Breast Cancer - Final results from PALLAS Trial
Dana-Farber's Erica Mayer, MD, MPH discusses the final analysis of the International Phase 3 PALLAS clinical trial presented at the 2021 San Antonio Breast Cancer Symposium.
Video
GS2-05 Update on the Combined TEXT and SOFT Trials
Dana-Farber's Meredith Regan, ScD presented an update on the SOFT/TEXT clinical trials at the 2021 San Antonio Breast Cancer Symposium.
News
Dana-Farber Researchers Present Findings at San Antonio Breast Cancer Symposium
Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 44th annual San Antonio Breast Cancer Symposium on December 7-10th.
News
Dana-Farber’s Judy Garber Is Recipient Of Brinker Award For Scientific Distinction
This year’s Brinker Award for Scientific Distinction in Clinical Research is being presented today to Judy Garber, M.D., M.P.H., Chief of the Division of Cancer Genetics and Prevention at Dana Farber Cancer Institute.
News
Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Some Patients
Uterine cancers that developed in patients treated with tamoxifen had fewer PI3K pathway mutations and may have instead been driven by tamoxifen-induced PI3K pathway activation, according to results presented at the 2021 San Antonio Breast Cancer Symposium.
News
Implantable Device Helps Predict Drug Therapy Efficacy
Dana-Farber investigators recently launched a trial of a miniature device that can be implanted into ovarian tumors to deliver microdoses of different drugs, with the goal of rapidly measuring their effectiveness in killing cancer cells.
Document
ASH 2021 Featured Oral Presentations
The Annual Meeting of the American Society of Hematology (ASH) will take place December 11-14th. To keep-up with latest advances, the live schedule of oral presentations by Dana-Farber faculty is attached for your convenience.
News
Targeted Drug Combination Shows Unprecedented Activity in Some Highly Aggressive Brain Tumors
Treatment with dabrafenib and trametinib yielded encouraging rate of durable responses in both high-grade and low-grade brain tumors carrying the rare BRAF v600E mutation. Study is first to show benefit of any targeted drugs in glioblastomas – the most aggressive brain tumor.
News
Discovery May Lead to Expanded Donor Pool for Stem Cell Transplants for Patients with Cancer
Researchers find that in many cases people with a condition known as clonal hematopoiesis can safely serve as stem cell transplant donors.
News
Dana-Farber Research Supports FDA Approval of Immunotherapy Drug Given After Surgery for Certain Patients with Kidney Cancer
Pembrolizumab is the first drug approved as adjuvant therapy for patients with kidney cancer considered at high risk of relapse.
News
Venetoclax Shown to Benefit Patients with Waldenström Macroglobulinemia, Including Some Who Relapsed After Previous Therapy
A drug that strips cancer cells of their quest for immortality represents an effective new option for patients with Waldenström macroglobulinemia, including those not helped by the only class of drugs currently approved to treat the disease, a clinical trial by Dana-Farber Cancer Institute investigators demonstrates.